Sirtex Medical Limited is an Australian public company generating revenue from the manufacturing and the distribution of treatments for liver cancer using small particle technology. Sirtex Medical is listed on the Australian Stock Exchange under the code SRX. Sirtex Medical employs around 245 people, and conducts operations in North and South America, Europe, Middle East, Africa and the Asia Pacific region. Sirtex Medical's head office is located in North Sydney, NSW.

Sirtex Medical engages in the manufacturing and distribution of treatments for liver cancer. The company's product can be used to deliver targeted, internal irradiation therapy directly to the tumour. This new therapy is called Selective Internal Radiation Therapy, or SIRT. Sirtex's core product, SIR-Spheres, are biocompatible radioactive microspheres, which act to destroy tumours, minimising the effects that this treatment has on normal liver tissue compared to conventional radiotherapy treatments and maximising the amount of tumour it can remove.

Learn more about our Company Reports

IBISWorld Company Profile Reports

Company profile reports provide key information on the Top 2000 earning companies in Australia. Reports include a written description of a company, its history, brands and products, contact details and key personnel, operating and legal structure, financial data, industries of involvement and business service providers.

Sample Data

Table of Contents

Company Details
Key Personnel
Growth & Ratios
Service Providers

Looking for our Industry reports?

Assess your competitors with powerful business tools that provide strategic insights and analysis on over 600 Australian industries.

Contact Us

Want to speak to a representative? Call us.